Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer

• Main Authors: David Schweer, J. Robert McCorkle, Jurgen Rohr, Oleg V. Tsodikov, Frederick Ueland, Jill Kolesar
• Format: Article
• Language: English
• Published: MDPI AG 2021-01-01
• Series: Biomedicines
• Subjects: ovarian cancer; mithramycin; Sp1; novel therapeutics; platinum-resistant
• Online Access: https://www.mdpi.com/2227-9059/9/1/70

Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-resistance. This article summarizes recent clinical developments related to mithramycin and postulates a role for the use of mithramycin, or its analog, in the treatment of platinum-resistant ovarian cancer.